<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802188</url>
  </required_header>
  <id_info>
    <org_study_id>MP-37-2019-4340</org_study_id>
    <nct_id>NCT03802188</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine in Systemic Lupus Erythematosus</brief_title>
  <official_title>Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Systemic lupus erythematosus, SLE is disease in which immune system is over-active causing
      inflammation in joints skin or any organ system. There are many areas where better approaches
      in SLE could improve outcomes. One example relates to hydroxychloroquine (HCQ) key drug which
      can reduce risk of serious disease flares. There are increasing concerns about eye damage
      main side effect with long-term use of HCQ. At present investigators cannot precisely predict
      which SLE patient is most likely to flare once HCQ is tapered. It is not clear what drives
      risk of eye damage. Investigators' study will fill these knowledge gaps. Investigators'
      hypothesis is that baseline demographic and clinical factors are associated with risk of SLE
      flare after HCQ taper/discontinuation and with risk of retinal toxicity in all HCQ exposed
      patients. Research will link and analyze data on 3700 SLE patients across Canada.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B OBJECTIVES B1 To evaluate in SLE patients who lower but do not discontinue HCQ factors
      associated with flare (significant increase in disease activity, augmentation of therapy or
      hospitalization for SLE).

      B2 To determine in SLE patients who discontinue HCQ factors associated with flare
      (significant increase in disease activity, therapy augmentation or hospitalization for SLE).

      B3 To evaluate temporal relationship between HCQ use and retinal toxicity in SLE patients and
      how this may be associated with demographic and clinical factors.

      B4 To assess SLE patient preferences for HCQ therapy and how preferences are associated with
      demographic and clinical factors.

      B5 To evaluate temporal relationship between antimalarial use and other forms of toxicity in
      SLE patients and how this may be associated with demographic and clinical factors.

      Team members have prospectively followed cohorts &gt; 3700 adult SLE patients (90% HCQ exposed)
      with collected and harmonized data on demographics and clinical factors. Team members
      (Bernatsky Abrahamowicz Fortin Hazlewood) are founding members of CAN-AIM CIHR-funded Drug
      Safety and Effectiveness Network team.

      Members have history of working with patients as research partners (Bartlett Li Bernatsky
      Fortin Hazlewood). Investigators' ties to stakeholders including patient research partners
      and Lupus Canada facilitates knowledge translation.

      METHODS C1 Cohorts: Investigators will use existing data on adult SLE patients enrolled into
      study cohorts in Montreal Quebec Halifax Winnipeg Calgary and Toronto.

      Investigators are members of national (Canadian Network for Improved Outcomes in SLE CaNIOS)
      and/or international (Systemic Lupus International Collaborating Clinics SLICC) research
      networks. CaNIOS and SLICC have worked decades on harmonized approach to
      prospectively-collected. Cohorts enroll unselected patients when they present to clinic. At
      annual assessments data are collected on drugs disease activity organ damage etc C2.1 Patient
      selection for Objective 1: At baseline and follow up visits records are made of patient HCQ
      doses. Starting with first visit with HCQ exposure investigators will determine how many
      patients are recorded as receiving lower dose or discontinuing HCQ at follow-up visit.
      Patients identified as having lowered HCQ dose will form sub-cohort for time-to-event
      (survival) analyses. Investigators will evaluate only first-ever lowering of HCQ. Analysis
      will evaluate patients from time zero (annual visit at which lower HCQ dose was recorded) to
      assess combined outcome of earliest of a) increase in SLEDAI-2K of at least 4 points and/or
      b) hospitalization for SLE and/or c) augmented SLE therapy defined as increase in HCQ or new
      start or increase in corticosteroids or other immunosuppressant. In addition to accepted
      minimal clinically significant SLEDAI-2K change investigators include drug changes and
      SLE-related hospitalizations.

      Patients studied in Objective 1 will be right censored if HCQ is discontinued completely;
      these will enter into analyses for Objective 2. Otherwise patients will be followed until
      outcome of interest or end of study.

      C2.3 Subject selection for Objective 2 Analyses will be similarly conducted but time zero
      will begin when individual discontinues HCQ. Objective 1 and 2 analyses conducted separately;
      patients who have HCQ dose lowered but then discontinued will be in analyses for Objective 1
      up to point of discontinuation then patients will be right censored for Objective 1. Subjects
      are able to contribute data (from the point of HCQ discontinuation) to analyses for Objective
      2. Patient can contribute to analyses for one or both objectives and contributing to
      Objective 3. If not right-censored patients will be followed until outcome of interest or end
      of study.

      C2.3 Subject selection for Objective 3 Outcome is retinal toxicity assessed in HCQ-exposed
      patients from time of first visit with HCQ exposure up to time of retinal toxicity
      documentation or end of study for patients without outcome. Exposure to CQ (relatively
      uncommon drug exposure) is also risk factor for retinal toxicity but essentially patients
      exposed to CQ will have prior exposure to HCQ.

      C3 Demographic and clinical factors C3.1 Variables assessed include sex age at SLE onset and
      race/ethnicity. Analyses adjusted for education as education can alter adherence.

      C3.2 Clinical factors for multivariable analyses include smoking BMI baseline disease
      activity malignancy data and renal damage. Baseline refers to time zero. Renal damage is
      captured with SLICC Damage Index measuring accumulated damage. Baseline disease activity
      measured by internationally used SLEDAI-2K reliable validated widely used global score
      index.Investigators will model time-varying drug exposures with step-up approach initially
      with baseline use ie current, recent, ever or total past dose. Investigators use
      sophisticated and novel weighted cumulative dose modelling to flexibly represent exposures
      accumulated by individual subjects up to given time-point corresponding to each risk set for
      time-to-event analyses. In multivariable analyses approach will allow investigators to
      explore how risk of retinal toxicity may depend on details of past HCQ exposure including not
      only total cumulative dose but temporal pattern of doses at various time in past with
      differential weights for early versus later exposures.

      C4 Outcome assessment: SLEDAI-2K and drugs are recorded. SLICC Damage Index has item for
      retinal damage and updated yearly.

      C5 Model development: Investigators will perform multivariable time-to-event analyses in
      patients who lower or discontinue HCQ. Data for outcomes are available longitudinally at
      annual visit with actual dates only available for addition/increase in corticosteroid or SLE
      hospitalization. For other outcomes investigators will deal with interval-censored data
      familiar issue in pharmacoepidemiology.

      Models include baseline demographics education BMI SLE duration SLEDAI-2K renal damage and
      medications. Simplistic survival analyses often assume linear effects of continuous
      covariates and impose conventional proportional hazards (PH) assumptions; investigators know
      that prognostic factors may have time-dependent and/or nonlinear effects that violate
      assumptions. Investigators will account for this. Methods account for possible changes in
      hazard ratio over time (violation of the PH) and allow estimation of relative risks (hazard
      ratios) and actual probabilities of event of interest occurring.

      Similar approach will be used for Objective 3 in time-to-event analyses of retinal toxicity
      in patients exposed to HCQ.

      Competing risks occur when subjects can experience one or more events that may compete with
      outcome of interest and hinder observation of event of interest or modify chances for event
      to occur. In sensitivity analyses investigators use competing risks models to simultaneously
      estimate associations between HCQ exposures and hazards of competing event.

      D POWER/SAMPLE CALCULATIONS D1 Power calculations for multivariate models Combined cohorts
      include over 3300 patients have exposed to HCQ. Patients have had lowering of dose 45% or
      discontinuation of HCQ during their follow-up. Power calculations are based on available data
      suggesting that 45%-60% of SLE patients may flare over ten years of follow-up.

      For baseline SLEDAI-2K assuming 35% of patients score less than 3 investigators would have
      90% power to detect unadjusted HR of 1.30 and adjusted HR of 1.37 for variable. Assuming 20%
      of patients have renal damage investigators will have 90% power to detect an unadjusted HR of
      1.37 and an adjusted HR of 1.45 for variable.

      E KNOWLEDGE TRANSLATION activities are informed by history of partnerships between
      investigators and knowledge-users directed by Dr. Linda Li Canada Research Chair in
      Patient-Oriented KT and Director of Knowledge Translation Research Program at UBC's Arthritis
      Research Centre of Canada.

      E1 Integrated KT Proposal developed in consultation patients from Lupus Canada patients
      Canadian Alliance of Patients with Arthritis (CAPA) and Singer Family Fund for Lupus
      Research. Wendy Singer (providing expertise health information dissemination and provides
      insight of SLE patient who has been affected by HCQ-induced retinal toxicity) will assist
      with educational tool developments. Co-PI Dr. Bartlett has over decade of work with patient
      partners through OMERACT (Outcome Measures in Rheumatology) and other organizations to help
      disseminate findings patient communities.

      E2 Dissemination via MyLupusGuide: Data on HCQ from current study will be incorporated into
      MyLupusGuide web-based patient-centred health-management tool developed by Dr. Fortin in
      partnership with Jack Digital Productions CaNIOS Lupus Canada. Development
      validation/dissemination of current version funded by CIHR operating and dissemination
      grants.

      E3 Clinicians and professional groups: Dr. Bernatsky is member of CRA Therapeutics Committee
      which advises CRA on policies related to drug use for rheumatic diseases. Group monitors
      information about adverse events related to drugs used in rheumatology including HCQ.
      Investigators submit abstracts to scientific meetings (American College of Rheumatology,
      European League Against Rheumatism, CRA meeting). Investigators will seek feedback on
      feasibility/approaches to integrate MyLupusGuide as gold standard for patient education tool
      concerning HCQ.

      E4 Informing future guidelines: Team member Dr. S. Keeling has already produced Canadian SLE
      care guidelines (funded by the CIHR and endorsed by the CRA and CaNIOS) . In 2019, again
      mandated by these groups, Dr. Keeling will spearhead guidelines for SLE therapies.

      E5 Health agency stakeholders: Investigators have connections Drug Safety and Effectiveness
      Network (DSEN) Health Canada's Marketed Health Product Directorate and Canadian Agency for
      Drugs and Technologies in Health (CADTH). Drs. Abrahamowicz and Bernatsky are co-leads
      DSEN-funded team.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of SLE flares with decrease or discontinuation of HCQ</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>In patients exposed to HCQ, presence or absence of SLE flare will be measure with SLEDAI-2K. The SLEDAI-2K is a reliable, validated, widely used global score index, consisting of 24 weighted clinical and laboratory variables of nine organ systems. The scores of descriptors range from 1 to 8, and the total score of the SLEDAI-2K is the sum of all 24 descriptor scores. An increase of 4 points or more has been validated as indicating a clinically significant increase in SLE disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants hospitalized with decrease or discontinuation of HCQ</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>In patients exposed to HCQ, presence or absence of hospitalization in cohort data will be measured in relation to HCQ dosage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of SLE flares relative to augmented SLE therapy</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Comparison of flares in SLE patients measured with SLEDAI-2K and augmented SLE therapy defined as an increase in HCQ or a new start or increase in corticosteroids (i.e. prednisone, methylprednisolone) or other immunosuppressant (azathioprine, mycophenolate, methotrexate, cyclophosphamide, belimumab, rituximab, chloroquine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of retinal toxicity and exposure to HCQ and retinal toxicity</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Renal damage is captured with the SLICC Damage Index, measuring accumulated damage since SLE onset. This validated index captures irreversible change in an organ or system (that has been present for at least 6 months). The renal item scores 1 for sustained heavy proteinuria, 2 for reduced glomerular filtration rate, and 3 for end-stage renal failure.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>SLE Cohort</arm_group_label>
    <description>Investigators will use existing data collected on adult SLE patients enrolled into respective study cohorts from participating centers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Qualitative group</arm_group_label>
    <description>For the interviews, patients with SLE who are currently or have taken Hydroxychloroquine will be recruited from rheumatology clinics in Calgary and Montreal to participate in an interview and/or participate in a brief survey.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators will use existing data collected on adult SLE patients who have been
        consecutively enrolled into the respective study cohorts of the participating researchers
        in Montreal , Quebec City, Halifax, Winnipeg, Calgary, and Toronto. The total exceeds 3,300
        SLE patients who have been exposed to HCQ.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years of age or over

          -  Must be diagnosed with Systemic Lupus Erythematosus (SLE)

          -  Must be exposed to hydroxychloroquine

          -  Must be enrolled at participating sites

        Exclusion Criteria:

          -  Under 18 years of age

          -  Not diagnosed with SLE

          -  Not exposed to hydroxychloroquine

          -  Not enrolled at participating sites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sasha Bernatsky, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Lee</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>44830</phone_ext>
    <email>Jennifer.Lee@rimuhc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Autumn Neville</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>44844</phone_ext>
    <email>autumn.neville@rimuch.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.aao.org/clinical-statement/revised-recommendations-on-screening-chloroquine-h</url>
    <description>AAO Quality of Care Secretariat, Hoskins Center for Quality Eye Care Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy Ophthalmology</description>
  </link>
  <link>
    <url>http://canaim.ca/about-us</url>
    <description>CAnadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research</description>
  </link>
  <link>
    <url>http://www.jrheum.org/content/42/12/2318.full.pdf</url>
    <description>Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent SLE.</description>
  </link>
  <link>
    <url>https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-012.html</url>
    <description>Racial and Ethnic Categories and Definitions</description>
  </link>
  <link>
    <url>https://doi.org/10.1002/art.1780370309</url>
    <description>The time-dependence of long-term prediction in lupus nephritis</description>
  </link>
  <link>
    <url>https://doi.org/10.1177%2F0962280217720947</url>
    <description>Competing risks modelling of cumulative effects of time-varying drug exposures</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012002/</url>
    <description>Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Administration and policy in mental health</description>
  </link>
  <reference>
    <citation>Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018 Oct;45(10):1426-1439. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1.</citation>
    <PMID>30173152</PMID>
  </reference>
  <reference>
    <citation>Jönsen A, Clarke AE, Joseph L, Belisle P, Bernatsky S, Nived O, Bengtsson AA, Sturfelt G, Pineau CA. Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 Sep;63(9):1233-7. doi: 10.1002/acr.20506.</citation>
    <PMID>21618451</PMID>
  </reference>
  <reference>
    <citation>Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013 Jun;40(6):831-41. doi: 10.3899/jrheum.120572. Epub 2013 Apr 15.</citation>
    <PMID>23588942</PMID>
  </reference>
  <reference>
    <citation>Levy DM, Peschken CA, Tucker LB, Chédeville G, Huber AM, Pope JE; Canadian Network for Improved Outcomes in SLE (CaNIOS) 1000 Faces Investigators, Silverman ED. Association of health-related quality of life in childhood-onset systemic lupus erythematosus with ethnicity: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res (Hoboken). 2014 Dec;66(12):1767-74. doi: 10.1002/acr.22363.</citation>
    <PMID>24821613</PMID>
  </reference>
  <reference>
    <citation>Aghdassi E, Zhang W, St-Pierre Y, Clarke AE, Morrison S, Peeva V, Landolt-Marticorena C, Su J, Reich H, Scholey J, Herzenberg A, Pope JE, Peschken C; LuNNET CaNIOS Investigators, Wither JE, Fortin PR. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol. 2011 Apr;38(4):658-66. doi: 10.3899/jrheum.100482. Epub 2010 Dec 15.</citation>
    <PMID>21159829</PMID>
  </reference>
  <reference>
    <citation>Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, Smith CD, Arbillaga HO, Gladman DD, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M; Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009 Jun;36(6):1200-8. doi: 10.3899/jrheum.080912. Epub 2009 Apr 15.</citation>
    <PMID>19369456</PMID>
  </reference>
  <reference>
    <citation>Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep;74(9):1706-13. doi: 10.1136/annrheumdis-2013-205171. Epub 2014 May 16.</citation>
    <PMID>24834926</PMID>
  </reference>
  <reference>
    <citation>Lee J, Dhillon N, Pope J. All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology (Oxford). 2013 May;52(5):905-9. doi: 10.1093/rheumatology/kes391. Epub 2013 Jan 9.</citation>
    <PMID>23307831</PMID>
  </reference>
  <reference>
    <citation>Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, Ng B, Marcus DM, Reveille JD, Suarez-Almazor ME. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008 Jul;27(7):883-9. doi: 10.1007/s10067-007-0816-6. Epub 2008 Jan 8.</citation>
    <PMID>18185905</PMID>
  </reference>
  <reference>
    <citation>Koneru S, Kocharla L, Higgins GC, Ware A, Passo MH, Farhey YD, Mongey AB, Graham TB, Houk JL, Brunner HI. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008 Aug;14(4):195-201. doi: 10.1097/RHU.0b013e31817a242a.</citation>
    <PMID>18636020</PMID>
  </reference>
  <reference>
    <citation>Mehat P, Atiquzzaman M, Esdaile JM, AviÑa-Zubieta A, De Vera MA. Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1706-1713. doi: 10.1002/acr.23191. Epub 2017 Sep 21. Review.</citation>
    <PMID>28086003</PMID>
  </reference>
  <reference>
    <citation>Leroux G, Costedoat-Chalumeau N, Hulot JS, Amoura Z, Francès C, Aymard G, Lechat P, Piette JC. Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann Rheum Dis. 2007 Nov;66(11):1547-8.</citation>
    <PMID>17934086</PMID>
  </reference>
  <reference>
    <citation>Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, Sylvestre MP. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012 Jul;71(7):1128-33. doi: 10.1136/annrheumdis-2011-200702. Epub 2012 Jan 12.</citation>
    <PMID>22241902</PMID>
  </reference>
  <reference>
    <citation>Widdifield J, Moura CS, Wang Y, Abrahamowicz M, Paterson JM, Huang A, Beauchamp ME, Boire G, Fortin PR, Bessette L, Bombardier C, Hanly JG, Feldman D, Bernatsky S; CAnadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM). The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery. J Rheumatol. 2016 May;43(5):861-8. doi: 10.3899/jrheum.151156. Epub 2016 Feb 15.</citation>
    <PMID>26879353</PMID>
  </reference>
  <reference>
    <citation>Moura CS, Abrahamowicz M, Beauchamp ME, Lacaille D, Wang Y, Boire G, Fortin PR, Bessette L, Bombardier C, Widdifield J, Hanly JG, Feldman D, Maksymowych W, Peschken C, Barnabe C, Edworthy S, Bernatsky S; CAN-AIM. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res Ther. 2015 Aug 3;17:197. doi: 10.1186/s13075-015-0713-3.</citation>
    <PMID>26235697</PMID>
  </reference>
  <reference>
    <citation>Sylvestre MP, Abrahamowicz M. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med. 2009 Nov 30;28(27):3437-53. doi: 10.1002/sim.3701.</citation>
    <PMID>19708037</PMID>
  </reference>
  <reference>
    <citation>Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2002 Jul;109(7):1377-82.</citation>
    <PMID>12093666</PMID>
  </reference>
  <reference>
    <citation>Sun X, Li X, Chen C, Song Y. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint. J Biopharm Stat. 2013;23(5):986-1003. doi: 10.1080/10543406.2013.813524.</citation>
    <PMID>23957511</PMID>
  </reference>
  <reference>
    <citation>Wynant W, Abrahamowicz M. Flexible estimation of survival curves conditional on non-linear and time-dependent predictor effects. Stat Med. 2016 Feb 20;35(4):553-65. doi: 10.1002/sim.6740. Epub 2015 Nov 6.</citation>
    <PMID>26542758</PMID>
  </reference>
  <reference>
    <citation>Wynant W, Abrahamowicz M. Impact of the model-building strategy on inference about nonlinear and time-dependent covariate effects in survival analysis. Stat Med. 2014 Aug 30;33(19):3318-37. doi: 10.1002/sim.6178. Epub 2014 Apr 22.</citation>
    <PMID>24757068</PMID>
  </reference>
  <reference>
    <citation>Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013 Jan-Feb;16(1):3-13. doi: 10.1016/j.jval.2012.08.2223.</citation>
    <PMID>23337210</PMID>
  </reference>
  <reference>
    <citation>Black N, Burke L, Forrest CB, Sieberer UH, Ahmed S, Valderas JM, Bartlett SJ, Alonso J. Patient-reported outcomes: pathways to better health, better services, and better societies. Qual Life Res. 2016 May;25(5):1103-12. doi: 10.1007/s11136-015-1168-3. Epub 2015 Nov 13.</citation>
    <PMID>26563251</PMID>
  </reference>
  <reference>
    <citation>Neville C, DaCosta D, Rochon M, Eng D, Fortin PR. Toward the development of a lupus interactive navigator to facilitate patients and their health care providers in the management of lupus: results of web-based surveys. JMIR Res Protoc. 2014 Dec 22;3(4):e65. doi: 10.2196/resprot.3349.</citation>
    <PMID>25533760</PMID>
  </reference>
  <reference>
    <citation>Bernatsky S, Peschken C, Fortin PR, Pineau CA, Urowitz MB, Gladman DD, Pope JE, Hudson M, Zummer M, Smith CD, Arbillaga HO, Clarke AE; Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Medication use in systemic lupus erythematosus. J Rheumatol. 2011 Feb;38(2):271-4. doi: 10.3899/jrheum.100414. Epub 2010 Nov 15. Erratum in: J Rheumatol. 2012 Mar;39(3):667. Pineau, Christi A [corrected to Pineau, Christian A].</citation>
    <PMID>21078722</PMID>
  </reference>
  <reference>
    <citation>Clarke AE, Urowitz MB, Monga N, Hanly JG. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada. Arthritis Care Res (Hoboken). 2015 Mar;67(3):431-6. doi: 10.1002/acr.22452.</citation>
    <PMID>25185936</PMID>
  </reference>
  <reference>
    <citation>Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, Ferguson DJ, Villalta D, Bizzaro N, Hanly JG, Fritzler MJ. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012 Nov;39(11):2104-10. doi: 10.3899/jrheum.120598. Epub 2012 Sep 1.</citation>
    <PMID>22942262</PMID>
  </reference>
  <reference>
    <citation>Furst DE, Clarke A, Fernandes AW, Bancroft T, Gajria K, Greth W, Iorga SR. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Lupus. 2013 Mar;22(3):268-78. doi: 10.1177/0961203312474087. Epub 2013 Jan 22.</citation>
    <PMID>23340996</PMID>
  </reference>
  <reference>
    <citation>Isenberg DA, Gladman D. The Systemic Lupus International Collaborating Clinics Group--origins and outcomes. Lupus. 2001;10(5):375-7.</citation>
    <PMID>11403271</PMID>
  </reference>
  <reference>
    <citation>Isenberg DA, Ramsey-Goldman R, Gladman D, Hanly JG. The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today. Lupus. 2011 Nov;20(13):1426-32. doi: 10.1177/0961203311421501. Erratum in: Lupus. 2012 Jan;21(1):114.</citation>
    <PMID>22095889</PMID>
  </reference>
  <reference>
    <citation>Lee J, Peschken CA, Muangchan C, Silverman E, Pineau C, Smith CD, Arbillaga H, Zummer M, Clarke A, Bernatsky S, Hudson M, Hitchon C, Fortin PR, Pope JE. The frequency of and associations with hospitalization secondary to lupus flares from the 1000 Faces of Lupus Canadian cohort. Lupus. 2013 Nov;22(13):1341-8. doi: 10.1177/0961203313505689. Epub 2013 Sep 18.</citation>
    <PMID>24048215</PMID>
  </reference>
  <reference>
    <citation>Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senécal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013 May;42:130-5. doi: 10.1016/j.jaut.2012.12.009. Epub 2013 Feb 12.</citation>
    <PMID>23410586</PMID>
  </reference>
  <reference>
    <citation>Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived O, Petri MA, Jacobsen S, Manzi S, Ginzler EM, Isenberg D, Rahman A, Gordon C, Ruiz-Irastorza G, Yelin E, Bae SC, Wallace DJ, Peschken CA, Dooley MA, Edworthy SM, Aranow C, Kamen DL, Romero-Diaz J, Askanase A, Witte T, Barr SG, Criswell LA, Sturfelt GK, Blanco I, Feldman CH, Dreyer L, Patel NM, St Pierre Y, Clarke AE. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014 Jan;73(1):138-42. doi: 10.1136/annrheumdis-2012-202099. Epub 2013 Jan 8.</citation>
    <PMID>23303389</PMID>
  </reference>
  <reference>
    <citation>Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, Senécal JL, Zummer M, Edworthy S, Sibley J, Pope J, Ensworth S, Ramsey-Goldman R, Hanly JG. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15(12):835-9.</citation>
    <PMID>17211987</PMID>
  </reference>
  <reference>
    <citation>Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 Aug;54(8):2550-7.</citation>
    <PMID>16868977</PMID>
  </reference>
  <reference>
    <citation>Lu M, Bernatsky S, Ramsey-Goldman R, Petri M, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler EM, Yelin E, Bae SC, Wallace DJ, Jacobsen S, Dooley MA, Peschken CA, Alarcón GS, Nived O, Gottesman L, Criswell LA, Sturfelt G, Dreyer L, Lee JL, Clarke AE. Non-lymphoma hematological malignancies in systemic lupus erythematosus. Oncology. 2013;85(4):235-40. doi: 10.1159/000350165. Epub 2013 Oct 2.</citation>
    <PMID>24107608</PMID>
  </reference>
  <reference>
    <citation>Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988 Aug;26(8):814-23.</citation>
    <PMID>3398608</PMID>
  </reference>
  <results_reference>
    <citation>Bernatsky S, Joseph L, Pineau CA, Tamblyn R, Feldman DE, Clarke AE. A population-based assessment of systemic lupus erythematosus incidence and prevalence--results and implications of using administrative data for epidemiological studies. Rheumatology (Oxford). 2007 Dec;46(12):1814-8.</citation>
    <PMID>18032538</PMID>
  </results_reference>
  <results_reference>
    <citation>Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):150-4.</citation>
    <PMID>1984192</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, Danoff D, Osterland CK, Yeadon C, Smith CD. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80-5.</citation>
    <PMID>9541091</PMID>
  </results_reference>
  <results_reference>
    <citation>Waldron N, Brown S, Hewlett S, Elliott B, McHugh N, McCabe C. 'It's more scary not to know': a qualitative study exploring the information needs of patients with systemic lupus erythematosus at the time of diagnosis. Musculoskeletal Care. 2011 Dec;9(4):228-38. doi: 10.1002/msc.221. Epub 2011 Oct 13.</citation>
    <PMID>21993962</PMID>
  </results_reference>
  <results_reference>
    <citation>Telek HH, Yesilirmak N, Sungur G, Ozdemir Y, Yesil NK, Ornek F. Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis. Doc Ophthalmol. 2017 Dec;135(3):187-194. doi: 10.1007/s10633-017-9607-9. Epub 2017 Aug 29.</citation>
    <PMID>28852896</PMID>
  </results_reference>
  <results_reference>
    <citation>Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. Review.</citation>
    <PMID>8607884</PMID>
  </results_reference>
  <results_reference>
    <citation>Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D'Cruz D, Khamashta MA, Gordon C. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011 May;50(5):982-8. doi: 10.1093/rheumatology/keq376. Epub 2011 Jan 18.</citation>
    <PMID>21245073</PMID>
  </results_reference>
  <results_reference>
    <citation>Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000 Mar;27(3):664-70.</citation>
    <PMID>10743805</PMID>
  </results_reference>
  <results_reference>
    <citation>Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer. 2004 Oct 4;91(7):1229-35. Review.</citation>
    <PMID>15305188</PMID>
  </results_reference>
  <results_reference>
    <citation>Hazlewood GS, Bombardier C, Tomlinson G, Thorne C, Bykerk VP, Thompson A, Tin D, Marshall DA. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology (Oxford). 2016 Nov;55(11):1959-1968. Epub 2016 Jul 31.</citation>
    <PMID>27477807</PMID>
  </results_reference>
  <results_reference>
    <citation>Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 Aug;34(8):937-44.</citation>
    <PMID>1859487</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011 Jun;14(4):429-37. doi: 10.1016/j.jval.2011.01.011.</citation>
    <PMID>21669367</PMID>
  </results_reference>
  <results_reference>
    <citation>Haase KR, Loiselle CG. Oncology team members' perceptions of a virtual navigation tool for cancer patients. Int J Med Inform. 2012 Jun;81(6):395-403. doi: 10.1016/j.ijmedinf.2011.11.001. Epub 2012 Jan 13.</citation>
    <PMID>22244817</PMID>
  </results_reference>
  <results_reference>
    <citation>Loiselle CG, Peters O, Haase KR, Girouard L, Körner A, Wiljer D, Fitch M. Virtual navigation in colorectal cancer and melanoma: an exploration of patients' views. Support Care Cancer. 2013 Aug;21(8):2289-96. doi: 10.1007/s00520-013-1771-1. Epub 2013 Mar 22.</citation>
    <PMID>23519565</PMID>
  </results_reference>
  <results_reference>
    <citation>Neville C, Da Costa D, Rochon M, Peschken CA, Pineau CA, Bernatsky S, Keeling S, Avina-Zubieta A, Lye E, Eng D, Fortin PR. Development of the Lupus Interactive Navigator as an Empowering Web-Based eHealth Tool to Facilitate Lupus Management: Users Perspectives on Usability and Acceptability. JMIR Res Protoc. 2016 May 30;5(2):e44. doi: 10.2196/resprot.4219.</citation>
    <PMID>27240666</PMID>
  </results_reference>
  <results_reference>
    <citation>Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002 May;61(5):409-13.</citation>
    <PMID>11959764</PMID>
  </results_reference>
  <results_reference>
    <citation>Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640-7.</citation>
    <PMID>17075810</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Dr. Sasha Bernatsky</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Retinal toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

